SOURCES SOUGHT
A -- Service for Animal Studies in the Pandemic Flu Project
- Notice Date
- 5/20/2009
- Notice Type
- Sources Sought
- NAICS
- 541380
— Testing Laboratories
- Contracting Office
- Department of Health and Human Services, Food and Drug Administration, Office of Acquisitions and Grants Services, 5630 Fishers Lane, Room 2129, Rockville, Maryland, 20857-0001
- ZIP Code
- 20857-0001
- Solicitation Number
- HHS-FDA-SS-09-1055658
- Archive Date
- 6/11/2009
- Point of Contact
- Tara R. Hobson, Phone: 3018279691, Doreen Williams , Phone: 301-827-3366
- E-Mail Address
-
Tara.Hobson@fda.hhs.gov, doreen.williams@fda.hhs.gov
(Tara.Hobson@fda.hhs.gov, doreen.williams@fda.hhs.gov)
- Small Business Set-Aside
- N/A
- Description
- Description: Service for Animal Studies in the Pandemic Flu Project This is a SOURCES SOUGHT NOTICE to determine the availability and capability of small businesses (including certified 8(a), Small Disadvantaged, and HUBZone firms; veteran and service-disabled veteran-owned small businesses, and woman-owned small businesses) for service for animal studies in the Pandemic Flu Project. This information is being sought for information and planning purposes only and shall not be construed as a solicitation or as an obligation on the part of the Food and Drug Administration (FDA). No official solicitation exists; therefore, please do not request a copy of a solicitation. If in the future an official solicitation is released, there is no guarantee that sources responding to this will be included on the source list. No telephone inquiries will be accepted. FDA may consider soliciting services for a one year contract. Objectives: The ultimate goal of this project is to complete animal studies in the Pandemic Flu Project. In the past few years, H5N1 strains of avian influenza have been shown to infect poultry in several parts of Asia and a highly pathogenic form for humans emerged in 1997. Human infections of this virus have been identified since then. Unlike other influenza viruses, H5N1 exhibits a wide range of unique pathologic features including hypercytokinemia, hemophagocytosis and neurologic involvement in some cases suggesting that pathogenesis and modes of spread of this virus may be different than seasonal flu strains. The potential for transmission of pandemic flue through blood transfusion and blood products is not known. H5N1 has been detected in blood of persons acutely infected with H5N1 virus using sensitive PCR methods. The possibility of a viremic period, before the onset of clinical symptoms and/or after symptom resolution, remains an important concern regarding blood safety. This knowledge gap in transfusion safety needs to be addressed in order to understand the infectivity of H5N1 in blood. Results from appropriate animal model studies could provide insights into the viremic period following H5N1 infection using an animal model that could help define a deferral period after exposure to pandemic influenza strains. Draft Scope of Work: This is an amendment to an existing contract which included a study with 32 mice and a study with 24 ferrets, each at two dose levels, has been completed. For the in vitro part, the following samples will be analyzed. 1.Mouse Study EID 50 of all lungs, spleen, brain, nasal turbinates and ileum (32 x 5 samples) RNA blood (88 samples) EID50 of blood samples (27 samples) RNA of lung (8), nasal turbinate (14) and brain (14) (14 each x 2 = 28 + 8 = 36 samples (including re-cutting of samples for RNA processing) 2.Ferret Study EID50 of 43 blood samples of 12 ferrets EID50 of 43 nasal wash, 12 lungs, 12 brains and 12 nasal turbinates (total = 122) RNA blood (144 samples) RNA of 47 + 7 tissues (12 lungs, 12 nasal turbinates, 12 brains and 11 spleen and 7 extra for verification) We may anticipate a labor hour type contract for one year. Viable parties shall provide the following: Part A. Capabilities and Technical Experience – Provide a capability statement describing how your company would provide animal studies in the Pandemic Flu Project as provided in the Draft Scope of Work. Part B. Size of Business- Please provide your business size and submit copies of any documentation such as letters or certificates to indicate the firm’s status. Part C. Organizational Conflict of Interest (OCI) - If any, provide disclosure of business activities of your company, your affiliates, your team members and affiliates of your team members which create either a conflict of interest or the appearance of a conflict of interest animal studies in the Pandemic Flu project. Part D. Cost Estimate - Provide a cost estimate for the services (i.e. hourly rates, hours/days) and the number of hours for animal studies in the Pandemic Flu Project as provided in the Draft Scope of Work. Part E. Small Business – Describe your ability to meet the requirements in accordance with 52.219.14 – Limitation on Subcontracting. Responses shall be: -identified with the Sources Sought number ; -no more than ten (10) pages in length; -not submit marketing materials; -submitted to the email as indicated above. FDA makes no implied or in fact contract by issuing this Sources Sought. Acknowledgement of receipt of responses will not be made, nor will respondents be notified of the FDA’s view of the information received. Do not send any material that requires a non-disclosure agreement or that may be business sensitive. Responses received that include a non-disclosure agreement or identify information that is business sensitive will not be accepted. Responses to this notice will not be returned.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/FDA/DCASC/HHS-FDA-SS-09-1055658/listing.html)
- Place of Performance
- Address: N29B RM4NN16 HFM-315, 880 Rockville Pike, Rockville, Maryland, 20892, United States
- Zip Code: 20892
- Zip Code: 20892
- Record
- SN01823924-W 20090522/090521004736-db41f927e24b614ea2f4935ae7bf2fcb (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |